Selective and brain-penetrant ACSS2 inhibitors target breast cancer brain metastatic cells

Breast cancer brain metastasis (BCBM) typically results in an end-stage diagnosis and is hindered by a lack of brain-penetrant drugs. Tumors in the brain rely on the conversion of acetate to acetyl-CoA by the enzyme acetyl-CoA synthetase 2 (ACSS2), a key regulator of fatty acid synthesis and protein...

Full description

Bibliographic Details

Published in:	Frontiers in pharmacology Vol. 15; p. 1394685
Main Authors:	Esquea, Emily M., Ciraku, Lorela, Young, Riley G., Merzy, Jessica, Talarico, Alexandra N., Ahmed, Nusaiba N., Karuppiah, Mangalam, Ramesh, Anna, Chatoff, Adam, Crispim, Claudia V., Rashad, Adel A., Cocklin, Simon, Snyder, Nathaniel W., Beld, Joris, Simone, Nicole L., Reginato, Mauricio J., Dick, Alexej
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 16.05.2024
Subjects:	acetate acetyl-CoA brain metastasis breast cancer cancer metabolism Pharmacology acetate computational-aided drug design font: italic formatted: left ACSS2 breast cancer acetyl-CoA brain metastasis cancer metabolism
ISSN:	1663-9812, 1663-9812
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!